[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chronic-lung-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chronic-lung-disease":32},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,16,0,[8,53,90,112,143,169,190,211,242,271,293,321,344,372,396,422],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100544852","pharmacy-led-transitions-of-care-intervention-to-improve-medication-adherence-100544852",false,"NCT06374277","Pharmacy-led Transitions of Care Intervention to Improve Medication Adherence","Pharmacy-led Transitions of Care Intervention to Address System-Level Barriers and Improve Medication Adherence in Socioeconomically Disadvantaged Populations","MedAAAction","Inclusion Criteria:\n\n* Medicaid or uninsured inpatients\n* 21 years or older\n* ≥2 of the complex chronic conditions during index admission or prescribed\u002Fusing ≥2 chronic medications for these conditions\n* Patients receiving chronic disease medications from the hospital pharmacy.\n* Patients will be eligible if they have multiple complex chronic conditions including diabetes, hypertension, high cholesterol, coronary artery disease, congestive heart failure, chronic lung disease, chronic kidney disease, arrhythmia, stroke, psychiatric disorders including depression and anxiety, or who are prescribed or using anticoagulants.\n\nExclusion Criteria:\n\n* Medicare and Medicaid dual eligible patients.\n* If the primary reason for the index admission is related to cancer, pregnancy, or a surgical procedure for an acute problem\n* If patients have diagnoses of active psychosis, substance abuse, or suicidal ideation during the index admission.\n* If the planned discharge location is not home.\n* If patients are part of an existing pharmacy discharge program.","ALL","18 Years",{"count":20,"type":21},388,"ESTIMATED","INTERVENTIONAL",[24],"NA","Socioeconomically disadvantaged populations with multiple chronic conditions have high rates of nonadherence to essential chronic disease medications after hospital discharge. Medication nonadherence after hospital discharge is significantly associated with increased mortality and higher rates of readmissions and costs among these patients. Major patient-reported barriers to essential medication use after hospital discharge among low-income individuals are related to social determinants of health (SDOH) and include: 1) financial barriers , 2) transportation barriers, and 3) system-level barriers. Although, medication therapy management services are important during care transitions, these services have not proven effective in improving medication adherence after hospital discharge, highlighting a critical need for innovative interventions. The Medication Affordability, Accessibility, and Availability in Care Transitions (Med AAAction) Study will test the effectiveness of a pharmacy-led care transitions intervention versus usual care through a pragmatic randomized controlled trial of 388 Medicaid and uninsured hospital in-patients with MCC from three large healthcare systems in Tennessee. The intervention will involve: 1) medications with zero copay, 2) bedside delivery then home delivery of medications, and 3) care coordination provided by certified pharmacy technicians\u002Fhealth coaches to assist with medication access, medication reconciliation, and rapid and ongoing primary care follow-up. We will examine the impact of the intervention during 12 months on 1) medication adherence (primary outcome) and 2) rapid primary care follow-up, 30-day readmissions, hospitalizations and emergency department visits, and costs. We will conduct key informant interviews to understand patient experience with the acre received during and after care transitions. By examining effectiveness of the intervention on outcomes including medication adherence, health care utilization, costs, and patient experience, this study will provide valuable results to health systems, payers, and policymakers to assist in future implementation and sustainability of the intervention for socioeconomically disadvantaged populations.",[27,28,29,30,31,32,33,34,35,36,37,38,39],"Diabetes","Hypertension","High Cholesterol\u002FHyperlipidemia","Coronary Artery Disease","Congestive Heart Failure","Chronic Lung Disease","Chronic Kidney Diseases","Arrythmia","Stroke","Depression","Anxiety","Pulmonary Embolism","Heart Attack","RECRUITING","2026-01-27",{"date":43,"type":44},"2026-01-29","ACTUAL",{"date":46,"type":44},"2024-04-06",{"date":48,"type":21},"2028-01-31",{"name":50,"class":51},"University of Tennessee","OTHER",2,{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":4,"eligibilityCriteria":59,"healthyVolunteers":60,"sex":17,"minAge":61,"maxAge":62,"enrollmentInfo":63,"targetDuration":4,"studyType":65,"phases":4,"briefSummary":66,"conditions":67,"keywords":73,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":89},"100620981","measuring-heart-health-in-both-term-preterm-and-unwell-newborn-babies-with-an-advanced-ultrasound-method-speckle-tracking-echocardiography-100620981","NCT07364682","Measuring Heart Health in Both Term, Preterm and Unwell Newborn Babies With an Advanced Ultrasound Method: Speckle Tracking Echocardiography","Assessment of Cardiac Function Using 2D Speckle Tracking Echocardiography (STE) in Neonates.","Inclusion Criteria:\n\n* Neonates who are inpatient at the Birmingham Women's Hospital\n* Confirmed diagnosis of acute pulmonary hypertension, congenital diaphragmatic hernia, hypoxic ischaemic encephalopathy, or bronchopulmonary dysplasia\u002Fchronic lung disease (defined by oxygen\u002Frespiratory support requirement at 36 weeks post menstrual\u002Fcorrected gestational age).\n\nOR\n\n* Health control (\\>36 weeks - well and on the postnatal ward)\n* Well preterm neonate (\\\u003C36 weeks) admitted to the NICU, transitional care or post-natal wards.\n* Informed consent obtained from parent(s) or legal guardian(s)\n\nExclusion Criteria:\n\n* Presence of major congenital heart disease (other than patent foramen ovale or patent ductus arteriosus).\n* Presence of other life-limiting congenital anomalies (other than CDH) or syndromes that could independently affect cardiac function.\n* Inability to obtain adequate echocardiographic images for STE analysis after reasonable attempts.\n* If the neonatal consultant or neonatal nurse caring for the neonate feels that the neonate is too unstable for inclusion in the study or that consent should not be sought from parents.",true,"0 Minutes","8 Weeks",{"count":64,"type":21},190,"OBSERVATIONAL","This study aims to improve how neonatologists check the heart function of newborn babies, especially those who are sick. While standard heart ultrasound scans are useful, a more advanced and sensitive technique called 2D speckle tracking echocardiography (STE) can detect subtle problems with how the heart muscle squeezes and relaxes. This may allow doctors to spot potential issues earlier.\n\nOur research will take place at Birmingham Women's Hospital. The investigators will perform these advanced, non-invasive heart scans on several groups of babies:\n\n1. Healthy term and premature babies, to establish a \"normal\" range of heart function.\n2. Babies who are unwell with specific conditions, including those with brain injury due to lack of oxygen at birth (HIE), chronic lung disease of prematurity (BPD), a hole in the diaphragm (CDH), or high blood pressure in their lungs (aPHN).\n\nThe heart scan is a standard, painless procedure. Using STE does not require any extra scanning time or cause any additional discomfort to the baby; the special images are taken during the routine scan. For many of the sick babies, these scans are already part of their normal clinical care.\n\nThe main goals of this observational study are to see if STE is a feasible and reliable tool in newborns, to establish normal values for healthy babies, and to track how heart function changes in sick babies during their illness and recovery.\n\nUltimately, the investigators hope this research will provide doctors with a better tool to assess heart health in newborns. This could lead to earlier, more accurate detection of heart problems and help guide treatment decisions to improve outcomes for these vulnerable infants.",[68,69,70,71,72],"Premature Baby","Pulmonary Hypertension of Newborn","Hypoxic Ischaemic Encephalopathy (HIE)","Congenital Diaphragmatic Hernia","Chronic Lung DIsease",[74,75,76,77],"Speckle Tracking Echocardiography","STE","Functional echocardiography","Neonatal Performed Echocardiography","NOT_YET_RECRUITING","2026-01-23",{"date":81,"type":44},"2026-01-26",{"date":83,"type":21},"2026-02-01",{"date":85,"type":21},"2028-03-01",{"name":87,"class":88},"Birmingham Women's NHS Foundation Trust","OTHER_GOV",1,{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":94,"acronym":95,"eligibilityCriteria":96,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":97,"targetDuration":4,"studyType":65,"phases":4,"briefSummary":99,"conditions":100,"keywords":101,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":105,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":89},"100111031","genetic-variants-and-susceptibility-to-diseases-of-prematurity-in-very-low-birth-weight-infants-100111031","NCT00710112","Genetic Variants and Susceptibility to Diseases of Prematurity in Very Low Birth-Weight Infants","CLD","Inclusion Criteria:\n\n* Infants born weighing less than 1500 grams\n\nExclusion Criteria:\n\n* Infants born with congenital heart disease (other than patent ductus arteriosus)\n* major congenital anomalies of the GI tract, respiratory tract, or kidneys",{"count":98,"type":21},1100,"The purpose of this study is to determine if sequence variations in genes involved in the development and function of vulnerable organs increases susceptibility to chronic lung disease (CLD) and other diseases affecting premature infants, such as necrotizing enterocolitis (NEC), sepsis, patent ductus arteriosus (PDA) and intraventricular hemorrhage (IVH). The study will also determine whether measurement of certain biomarkers in serum will identify infants who will develop these complications of prematurity. Previous studies from this institution and others have identified genetic variants in some genes, such as toll like receptor genes are associated with higher risk of CLD or NEC. The interaction of these variants with other gene variants that can influence the risk of these diseases remains unclear.",[32],[95,102,103,104],"VLBW infants","Toll like Receptors","Biomarkers",{"date":81,"type":44},{"date":107,"type":4},"2006-06",{"date":109,"type":21},"2028-06",{"name":111,"class":51},"Medical College of Wisconsin",{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":118,"eligibilityCriteria":119,"healthyVolunteers":11,"sex":17,"minAge":120,"maxAge":121,"enrollmentInfo":122,"targetDuration":4,"studyType":65,"phases":4,"briefSummary":124,"conditions":125,"keywords":129,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":89},"100441240","fitness-and-lung-function-among-survivors-of-heart-transplant-leukemia-and-infant-bpd-through-exercise-100441240","NCT05025774","Fitness and Lung Function Among Survivors of Heart Transplant, Leukemia and Infant BPD Through Exercise","Fitness and Lung Function Among Survivors of Heart Transplant, Leukemia and Infant Bronchopulmonary Dysplasia (BPD, Also Known as Chronic Lung Disease of Prematurity) Through Exercise (FLASHLITE)","FLASHLITE","Inclusion Criteria:\n\n* Cases:\n\n  * Acute lymphoblastic leukemia survivor, OR living with chronic lung disease of prematurity, OR living with heart transplant\n  * 8-25 years old\n  * Height: ≥ 48 inches\n  * Ambulatory without assistance\n  * English speaking\n  * Normotensive (\\\u003C95th percentile for age; okay if managed with antihypertensive medication)\n  * SpO2 \\>92%\n  * Not pregnant\n  * ALL survivor specific: must have completed therapy ≥ 3 months prior to study entry\n* Controls\n\n  * 8-25 years old\n  * Height: ≥ 48 inches\n  * Ambulatory without assistance\n  * English speaking\n  * No history of arrhythmia or known cardiac dysfunction at baseline\n  * Normotensive (\\\u003C95th percentile for age; okay if managed with antihypertensive medication)\n  * SpO2 \\>95%\n  * Not pregnant\n\nExclusion Criteria:\n\n* Cases:\n\n  * ALL specific: received cranial radiation, bone marrow transplant recipients\n  * Investigator or patient's primary physician deems the patient unsuitable for the study\n* Controls:\n\n  * History of malignancy, CLD or HT or any other diagnosis which may reduce cardiorespiratory function\n  * Investigator deems the patient unsuitable for the study","8 Years","25 Years",{"count":123,"type":21},90,"This study aims to more accurately assess cardiac function, ventilation and exercise capacity in a non-invasive fashion, and to better characterize exercise intolerance in the setting of three populations of individuals with chronic diseases of childhood (acute lymphoblastic leukemia (ALL), chronic lung disease (CLD) of prematurity, and post-heart transplant (HT))",[32,126,127,128],"Chronic Obstructive Pulmonary Disease","Acute Lymphoblastic Leukemia","Heart Transplant",[130,131,132,133],"Quality of life","Lung function","Fitness","Exercise","2025-11-21",{"date":136,"type":44},"2025-11-24",{"date":138,"type":44},"2025-03-14",{"date":140,"type":21},"2026-12-01",{"name":142,"class":51},"Masonic Cancer Center, University of Minnesota",{"id":144,"slug":145,"hasResults":11,"nctId":146,"briefTitle":147,"officialTitle":148,"acronym":4,"eligibilityCriteria":149,"healthyVolunteers":11,"sex":17,"minAge":150,"maxAge":4,"enrollmentInfo":151,"targetDuration":4,"studyType":65,"phases":4,"briefSummary":153,"conditions":154,"keywords":157,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":168},"100505816","parametric-response-mapping-prm-for-the-detection-of-chronic-lung-injury-in-hematopoietic-cell-transplant-recipients-100505816","NCT05866302","Parametric Response Mapping (PRM) for the Detection of Chronic Lung Injury in Hematopoietic Cell Transplant Recipients","Parametric Response Mapping (PRM) for the Detection of Chronic Lung Injury in Hematopoietic Cell Transplant Recipients. A Multi-center, Observational Trial.","Inclusion Criteria:\n\n* For both Cohorts 1 and 2:\n* Age ≥ 36 months. There is no upper age limit.\n* Receipt of an allogeneic HCT. There are no exclusions to study entry based upon primary diagnosis, hematopoietic cell source, conditioning regimen, donor type, degree of donor-recipient HLA match, or current organ function.\n* All patients and\u002For their parents or legal guardians must sign a written informed consent. Assent, when appropriate, will be obtained according to institutional guidelines.\n* Cohort 1 (Chronic Graft Versus Host Disease): Diagnosis of chronic GVHD in at least 1 organ system within the prior 3 months. NIH Consensus Criteria for chronic GVHD are required to establish the diagnosis. (https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F25529383\u002F)\n* Cohort 2 (Chronic Lung Disease, CLD) Diagnosis of CLD within the prior 100 days, including either Bronchiolitis Obliterans Syndrome (BOS) or Restrictive lung disease (RLD), with each defined as follows: Bronchiolitis Obliterans Syndrome (BOS): (NIH Consensus Criteria)31 a.FEV1 \\\u003C 75% predicted, with a decline in absolute FEV1 \\> 10% compared to pretransplant baseline or within the prior 2 years, b.FEV1\u002FVC or FEV1\u002FFVC \\\u003C 0.7 , c. Absence of an alternative diagnosis, including COPD exacerbation, asthma, and active respiratory tract infection, as determined by appropriate clinical investigations that may include chest imaging, microbiologic cultures, and\u002For bronchoscopy, d. One of two supportive features of BOS: i. Evidence of air trapping by PFTs: RV\\>120%, or elevated RV\u002FTLC (\\>20% of predicted), ii. High resolution chest CT with inspiratory and expiratory cuts that show findings that are consistent with small airways disease including (but not exclusive of) air trapping, bronchial wall thickening, or bronchiectasis. Restrictive Lung Disease (RLD): a. ≥ 20% decline in FEV1 from baseline, coupled with ≥ 10% decline in total lung capacity (TLC) from baseline. If measurements of TLC are not available, then a ≥ 20% decline in FVC from baseline may be substituted for RLD.32, b.Radiographic opacities or infiltrates on chest radiograph or CT. Such changes may include, but are not limited to the presence of ground glass opacities, reticular changes, septal thickening, fibrotic changes or areas of consolidation.\n* Patients unable to perform PFT. For cohort 1, patient's too young (or physically unable) to perform PFT's remain eligible provided they meet all other eligibility criteria. For cohort 2, children too young (or physically unable) to perform PFT's are eligible provided they exhibit both clinical and radiographic features (on CT) consistent with CLD. Clinical features would include dyspnea, cough, and\u002For SpO2 \\\u003C 93% on room air. Radiographic features may include, but are not limited to the presence of air trapping, bronchial wall thickening, or bronchiectasis.\n\nExclusion Criteria:\n\n* Relapse of a patient's primary malignancy post-HCT, or the development of any secondary \"hematologic\" malignancy post-HCT.\n* The presence of an active, uncontrolled infection.\n* Patients who would require intubation solely for the purposes of obtaining a CT scan for PRM imaging. (In contrast, if a clinical CT is being performed as routine medical care to evaluate a patient's lung function, the patient is eligible and PRM imaging may be performed from that CT.)","36 Months",{"count":152,"type":21},375,"The study will have two separate patient cohorts: Cohort 1 will include patients with newly diagnosed chronic graft versus host disease (GVHD), whereas cohort 2 will include patients with newly diagnosed chronic lung disease (CLD). For cohort 1, the primary objective will be to characterize PRM metrics at the onset of chronic GVHD and determine if a PRM signature is present that will predict 1-year CLD free survival. For cohort 2, the primary objective will focus on characterizing PRM at the onset of CLD and determine if PRM can predict the trajectory in lung function decline in affected patients.",[32,155,156],"Hematopoietic Cell Transplantation","Graft Versus Host Disease",[158],"Parametric response mapping","2025-10-16",{"date":161,"type":44},"2025-10-20",{"date":163,"type":44},"2023-05-30",{"date":165,"type":21},"2028-05",{"name":167,"class":51},"University of Michigan Rogel Cancer Center",6,{"id":170,"slug":171,"hasResults":11,"nctId":172,"briefTitle":173,"officialTitle":174,"acronym":4,"eligibilityCriteria":175,"healthyVolunteers":60,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":176,"targetDuration":4,"studyType":22,"phases":178,"briefSummary":179,"conditions":180,"keywords":4,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":182,"startDateStruct":184,"completionDateStruct":186,"leadSponsor":188,"locationsCount":4},"100552567","using-parent-engagement-to-improve-the-wellbeing-of-black-premature-infants-with-chronic-lung-disease-100552567","NCT06474767","Using Parent Engagement to Improve the Wellbeing of Black Premature Infants With Chronic Lung Disease","Addressing Health Disparities in Chronic Lung Disease for Preterm Infants Through Parent Engagement","Inclusion Criteria:\n\n* Parent\u002Flegal guardian of child born prior to 37 weeks gestational age\n* Parent\u002Flegal guardian of child with diagnosis of chronic lung disease or bronchopulmonary dysplasia, as defined by the child's clinical team at the time of hospital discharge\n* Parent\u002Flegal guardian of child who identifies that child's race as Black\n* English speaking\n\nExclusion Criteria:\n\n* Parent\u002Flegal guardian of child enrolled in palliative care or hospice services at time of hospital discharge\n* Parent\u002Flegal guardian of child older than 12 months chronological age",{"count":177,"type":21},30,[24],"The goal of this pilot study is to test the feasibility and acceptability of a collaborative goal setting intervention to improve parent engagement of Black preterm infants with chronic lung disease in primary care. Preliminary impact on child and parent outcomes will also be explored.\n\nThe main questions it aims to answer are: 1) Will parents complete a pre-visit questionnaire that asks about goals for the child? 2) Does use of the pre-visit questionnaire help parents to achieve self-identified goals?\n\nParticipants will fill out a pre-visit questionnaire prior to the child's well visit. The participants will then complete two surveys after the visit (1 week and 2 months after).",[32],"2025-09-10",{"date":183,"type":44},"2025-09-16",{"date":185,"type":21},"2026-07-01",{"date":187,"type":21},"2027-06-30",{"name":189,"class":51},"Johns Hopkins University",{"id":191,"slug":192,"hasResults":11,"nctId":193,"briefTitle":194,"officialTitle":194,"acronym":4,"eligibilityCriteria":195,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":196,"enrollmentInfo":197,"targetDuration":4,"studyType":65,"phases":4,"briefSummary":199,"conditions":200,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":202,"lastUpdatePostDateStruct":203,"startDateStruct":205,"completionDateStruct":207,"leadSponsor":209,"locationsCount":89},"100604611","prospective-validation-of-the-novel-pvd-b65-risk-score-in-patients-with-chronic-lung-disease-and-pulmonary-hypertension-100604611","NCT07151768","Prospective Validation of the Novel PVD-B65 Risk Score in Patients With Chronic Lung Disease and Pulmonary Hypertension","Inclusion Criteria:\n\n* Eligibility criteria\n\n  1. Adult patients ≥ 18 years of age with chronic lung disease diagnosed via CT chest and\u002For PFT data and pre-capillary pulmonary hypertension diagnosed via right-heart catheterization (RHC, mPAP \\> 20 mmHg, PVR \\> 2 WU, and PCWP ≤ 15 mmHg)\n\n     1. Chronic lung disease diagnoses will include: COPD, IPF, other pulmonary fibrosis, non-fibrotic ILD, combined pulmonary fibrosis and emphysema, and advanced pulmonary sarcoidosis with parenchymal involvement\n     2. PFT criteria will include an FEV1\u002FFVC \\\u003C 0.70 for the diagnosis of COPD\n  2. Willingness to make return visits and be available by telephone for the duration of the study.\n  3. Ability to participate in necessary testing, including ambulatory testing\n\nExclusion Criteria:\n\n* Exclusion criteria\n\n  1. Patients with pulmonary hypertension but without associated chronic lung disease (i.e. idiopathic or group 1 PAH, PH with post-capillary component defined as PCWP \\> 15 mmHg or group 2 PAH, CTEPH or group 4 PH, group 5 PH aside from sarcoidosis with parenchymal involvement)\n  2. Patients with uncontrolled severe systemic disease that could influence life expectancy (i.e. uncontrolled cardiovascular disease, active malignancy, etc.)\n  3. Prior lung and\u002For heart transplantation","99 Years",{"count":198,"type":21},100,"Prospective observational study to determine if the PVD-B65 risk score for one-year mortality in patients with chronic lung disease and pulmonary hypertension (CLD-PH) can accurately risk stratify these patients and successfully predict one-year mortality from time of pulmonary hypertension diagnosis. PVD-B65 risk score was developed in a retrospective cohort of patients with CLD-PH, utilizing the presence of pulmonary fibrosis without emphysema, pulmonary vascular resistance (PVR) \\> 5 woods units (WU), 6-minute walk distance (6MWD) \\\u003C 150 meters, B-natriuretic type peptide (BNP) \\> 200 pg\u002FmL or N-terminal pro-natriuretic type peptide (NT-proBNP) \\> 300 pg\u002FdL, and age \\> 65 years as the score components.",[32,201],"Pulmonary Hypertension","2025-08-25",{"date":204,"type":44},"2025-09-03",{"date":206,"type":21},"2025-09-01",{"date":208,"type":21},"2028-09-01",{"name":210,"class":51},"Temple University",{"id":212,"slug":213,"hasResults":11,"nctId":214,"briefTitle":215,"officialTitle":216,"acronym":217,"eligibilityCriteria":218,"healthyVolunteers":11,"sex":17,"minAge":219,"maxAge":220,"enrollmentInfo":221,"targetDuration":4,"studyType":22,"phases":223,"briefSummary":224,"conditions":225,"keywords":228,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":233,"lastUpdatePostDateStruct":234,"startDateStruct":236,"completionDateStruct":238,"leadSponsor":240,"locationsCount":89},"100600474","paediatric-post-tb-pulmonary-rehab-study-100600474","NCT07097961","Paediatric Post-TB Pulmonary Rehab Study","Paediatric Post-TB Home-based Pulmonary Rehabilitation Feasibility Study","PPT Rehab","Inclusion Criteria:\n\n* Aged 6-17 years\n* Previously diagnosed with post-TB lung disease,\n* Willing to remain in the study catchment area during the study period\n* Able to participate in mild-to-moderate physical activity (late inclusion criterion)\n\nExclusion Criteria:\n\n* Currently participating in another rehabilitation program\n* Residence outside the Kampala metropolitan area\n* Active respiratory infection (late exclusion criterion)","6 Years","17 Years",{"count":222,"type":21},40,[24],"The goal of this clinical trial is to learn if a home-based pulmonary rehabilitation program is feasible and acceptable for children ages 6-15 who have recently completed treatment for pulmonary tuberculosis. The main questions it aims to answer are:\n\nCan children and caregivers follow a 6-week rehabilitation program?\n\nIs the program acceptable and feasible for children and caregivers?\n\nResearchers will also explore preliminary changes in walking distance and quality of life.\n\nParticipants will:\n\nAttend a clinic visit for baseline testing, including a 6-minute walk test (6MWT) and the St. George's Respiratory Questionnaire (SGRQ)\n\nReceive exercise instructions and a pedometer\n\nComplete home-based walking and wall sit exercises twice per week for 6 weeks\n\nReceive weekly follow-up from study staff (by phone or home visit)\n\nReturn to clinic at 6 weeks for follow-up testing",[226,32,227],"Tuberculosis in Children","Post Tuberculosis",[229,230,231,232],"Post-TB lung disease","Uganda","Pulmonary rehabilitation","pediatric tuberculosis","2025-08-06",{"date":235,"type":44},"2025-08-11",{"date":237,"type":44},"2025-07-29",{"date":239,"type":21},"2026-02-23",{"name":241,"class":51},"University of Iowa",{"id":243,"slug":244,"hasResults":11,"nctId":245,"briefTitle":246,"officialTitle":247,"acronym":248,"eligibilityCriteria":249,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":250,"enrollmentInfo":251,"targetDuration":4,"studyType":22,"phases":253,"briefSummary":254,"conditions":255,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":262,"lastUpdatePostDateStruct":263,"startDateStruct":265,"completionDateStruct":267,"leadSponsor":269,"locationsCount":89},"100541215","reducing-chronic-breathlessness-in-adults-by-following-a-self-guided-internet-based-supportive-intervention-self-breathe-100541215","NCT06326957","Reducing Chronic Breathlessness in Adults by Following a Self-guided, Internet Based Supportive Intervention (SELF-BREATHE)","A Multicentre, Randomised Controlled Trial Comparing Usual NHS Care to a Self-guided Internet-based Intervention (SELF-BREATHE) Plus Usual NHS Care to Reduce Breathlessness in Adults Living With Chronic Breathlessness","SELF-BREATHE","Inclusion Criteria:\n\n* Adults ≥ 18 years of age\n* Chronic Breathlessness at rest and \u002F or exertion\n* Chronic Breathlessness (CB) defined as breathlessness that persists (\\>3months) despite pharmacological treatment of the underlying disease including, but not limited to; cancer, chronic obstructive pulmonary disease (COPD), interstitial lung disease (ILD), bronchiectasis, chronic fibrotic lung disease following SARS-CoV2 infection\n* Medical Research Council (MRC) dyspnea score ≥ 2 (MRC 2= short of breath when hurrying on the level or walking up a slight hill\n* Availability to a computer, tablet, or smart phone with internet access\n* Able to provide informed consent.\n\nExclusion Criteria:\n\n* Breathlessness of unknown cause\n* Primary diagnosis of chronic hyperventilation syndrome\n* Currently participating in a rehabilitation programme e.g.,pulmonary\u002Fcardiac rehabilitation (patients that have completed PR \\>4-weeks will be eligible).","110 Years",{"count":252,"type":21},246,[24],"Background:\n\nSome health conditions make breathing difficult and uncomfortable. When this happens every day, it is called chronic breathlessness. Over 3 million people living with heart and lung disease have chronic breathlessness in the UK.\n\nBreathlessness is very difficult for patients themselves and their families, resulting in disability and feelings of fear, distress, and isolation. Due a to lack of supportive breathlessness services many patients frequently attend hospital Accident and Emergency (A\\&E) departments seeking help.\n\nGiven the on-going challenges faced by the National Health Service (NHS) in the United Kingdom, such as long waiting times, staff shortages, increased demand for services because of the COVID-19 pandemic, there is an urgent need to develop new ways to support those living with chronic breathlessness. One potential solution is to offer support online, as it is estimated that in the UK, 7 out of every 10 people with chronic breathlessness are internet users.\n\nWith the help of patients and NIHR funding the research team lead by Dr Charles Reilly, developed an online breathlessness supportive website called SELF-BREATHE. SELF-BREATHE provides information and self-management tools such as breathing exercises, that patients can do at home themselves.\n\nSELF-BREATHE has been tested as part of its development. SELF-BREATHE is acceptable and valued by patients. But what is unknown is whether SELF-BREATHE improves patients' breathlessness and their life? This is the question this research seeks to answer.\n\nAims\n\n1. To test if using SELF-BREATHE for six-weeks improves patients' breathlessness, their quality of life and whether SELF-BREATHE should be offered within the NHS\n2. To see if patients opt to continue to use SELF-BREATHE after six-weeks and what benefits this may have for patients.\n\nMethods\n\nThe research team are undertaking a randomised controlled trial. For this, 246 people living with chronic breathlessness will be recruited in to this study. Each person will be randomly chosen by a computer to continue with their usual care or their usual care plus access to SELF-BREATHE. All study participants will complete questionnaires at the start of the study, thereafter at seven and twelve weeks after randomisation.\n\nThese questionnaires will ask patients about 1) their breathlessness and its effect on their life and 2) planned and unplanned hospital visits. At the end of the study, we will compare answers to these questionnaires between the two groups at seven and 12 weeks.\n\nThis will tell if SELF-BREATHE improved patients' breathlessness and reduced their need for unplanned hospital visits e.g., A\\&E attendances due to breathlessness.",[126,256,257,258,259,260,261,32],"Bronchiectasis","Interstitial Lung Disease","Lung Cancer","Asthma","Dyspnea","Fibrotic Lung Disease","2025-06-10",{"date":264,"type":44},"2025-06-13",{"date":266,"type":44},"2024-07-04",{"date":268,"type":21},"2028-07",{"name":270,"class":51},"King's College Hospital NHS Trust",{"id":272,"slug":273,"hasResults":11,"nctId":274,"briefTitle":275,"officialTitle":276,"acronym":4,"eligibilityCriteria":277,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":278,"targetDuration":4,"studyType":65,"phases":4,"briefSummary":280,"conditions":281,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":284,"lastUpdatePostDateStruct":285,"startDateStruct":287,"completionDateStruct":289,"leadSponsor":291,"locationsCount":89},"100561597","awareness-of-individuals-with-chronic-lung-disease-about-climate-change-heat-waves-air-pollution-and-physical-activity-100561597","NCT06592235","Awareness of Individuals with Chronic Lung Disease About Climate Change, Heat Waves, Air Pollution and Physical Activity","Assessment of Awareness of Individuals with Chronic Lung Disease on Climate Change, Heat Waves, Air Pollution, and Their Interactions with Physical Activity","Inclusion criteria for the study:\n\n* Being 18 years of age or older,\n* Having a chronic lung disease (COPD, asthma, bronchiectasis, cystic fibrosis, interstitial lung disease) and being referred to the Cardiopulmonary Rehabilitation Unit of Hacettepe University, Faculty of Physical Therapy and Rehabilitation for cardiopulmonary physiotherapy and rehabilitation,\n* Being clinically stable,\n* Using a smartphone with a pedometer,\n* To cooperate with the tests to be conducted,\n* Being willing to participate in the study.\n\nExclusion criteria:\n\n* Having had an acute exacerbation or having changed medication in the last month,\n* Having a severe cardiovascular, orthopedic or neurological problem that may affect the tests.",{"count":279,"type":21},80,"Climate change is characterized by global temperature increase, melting of glaciers and increasing temperature of ocean waters. Increase in greenhouse gases such as nitrogen and carbon dioxide negatively affects air and water quality. Extreme events such as extreme heat waves, floods and hurricanes are events seen with climate change. It is known that climate change and air pollution have negative effects on public health. Its adverse effects are often seen in individuals with rhinosinusitis, asthma and chronic obstructive pulmonary disease. Air pollution is expected to increase due to the ongoing economic growth and population growth worldwide, resulting in more respiratory diseases and disease burden. This study aims to assess the awareness level of individuals with chronic lung disease on climate change, heat waves, air pollution and their interaction with physical activity and anxiety and depression levels, and to better understand the experiences of patients and learn their perspectives. Within the scope of the study, it is planned to provide patients brief information on this subject and receive feedback about this information.",[282,32,283],"Climate Change","Air Pollution","2024-09-09",{"date":286,"type":44},"2024-09-19",{"date":288,"type":44},"2024-09-01",{"date":290,"type":21},"2025-08-01",{"name":292,"class":51},"Hacettepe University",{"id":294,"slug":295,"hasResults":11,"nctId":296,"briefTitle":297,"officialTitle":298,"acronym":4,"eligibilityCriteria":299,"healthyVolunteers":11,"sex":17,"minAge":300,"maxAge":301,"enrollmentInfo":302,"targetDuration":4,"studyType":22,"phases":304,"briefSummary":305,"conditions":306,"keywords":307,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":312,"lastUpdatePostDateStruct":313,"startDateStruct":315,"completionDateStruct":317,"leadSponsor":319,"locationsCount":89},"100559095","prevention-of-chronic-lung-disease-cld---prevention-study-100559095","NCT06559670","Prevention of Chronic Lung Disease (CLD - Prevention Study)","Prevention of Chronic Lung Disease: New High Risk Profile for Early Detection and Management Starting From Perinatal Life (CLD - Prevention Study)","Inclusion Criteria:\n\nInfants with gestational age \\\u003C 32 weeks with at least one of the following signs of acute respiratory failure within the first 24 hours of life:\n\n* need for mechanical ventilation;\n* need for noninvasive respiratory support;\n* need for oxygen administration;\n* need for surfactant administration\n\nExclusion Criteria:\n\n* Congenital malformations\n* Neuromuscular diseases.","1 Hour","24 Hours",{"count":303,"type":21},42,[24],"Primary endpoint:\n\n\\- prospectively identify potential biomarkers able to predict the severe course of pulmonary funcion in the first 12 months of life and realize a new profile to early identify hugh risk newborns\n\nSecondary endpoints:\n\n* detect genetic variance causation model (by MiSeq Illumina platform) correlating with severe pulmonary dysfunction and asthma development;\n* detect MIcroRNAs as well as anti- and pro-inflammatory cytokine variations (MIP-1α, MCP-1, IL-8, TNF-α, IFN-ɣ, IL-10) correlating with the severity of pulmonary dysfunction in the first 12 months of life and the risk of asthma development\n\nPopulation: preterm infants with gestational age \\\u003C 32 weeks who have suffered from acute respiratory insufficiency at birth\n\nIntervention:\n\n* Assessment of prenatal risk factors.\n* Collection of the following biological specimens: 1) a vaginal swab from the mothers of enrolled infants 2) a placenta sample 3) an arterial or venous cord blood sample at birth 4) peripheral blood samples from enrolled infants: the first within 48 hours of life, the subsequent ones at 7 and 28 days of life and at 6 and 12 months of age 5) bronchoalveolar lavage (BALF) samples exclusively in infants intubated for clinical reasons within the first 24 hours of life, at 7 and 28 days of life. 6) first meconium sample issued and subsequent stool samples at 7 and 28 days of life and at 6 and 12 months of age, of enrolled infants\n* Respiratory Functionality Testing at 6 and 12 months of age",[32],[32,308,309,310,311],"Newborns","COPD","Preterm infants","Bronchopulmonary dysplasia","2024-08-14",{"date":314,"type":44},"2024-08-19",{"date":316,"type":21},"2024-09",{"date":318,"type":21},"2026-09",{"name":320,"class":51},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":322,"slug":323,"hasResults":11,"nctId":324,"briefTitle":325,"officialTitle":326,"acronym":4,"eligibilityCriteria":327,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":328,"enrollmentInfo":329,"targetDuration":4,"studyType":22,"phases":331,"briefSummary":332,"conditions":333,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":335,"lastUpdatePostDateStruct":336,"startDateStruct":338,"completionDateStruct":340,"leadSponsor":342,"locationsCount":89},"100558033","effects-of-an-automatic-oxygen-titration-system-in-people-with-hypoxemia-during-exercise-training-100558033","NCT06545851","Effects of an Automatic Oxygen Titration System in People With Hypoxemia During Exercise Training","Automatic Oxygen Titration Versus Constant Oxygen Flow Rates During Exercise Training in Hypoxemic People With Chronic Lung Disease - a Randomized, Double-blind, Controlled Cross-over Pilot Study","Inclusion Criteria:\n\n* Chronic lung disease\n* Hypoxemia (pO2\\\u003C 55mmHg) under room air conditions (rest or during exercise) or SpO2\\\u003C88% during exercise\n* established Long-term oxygen therapy or given indication for a Long-term oxygen therapy\u002F supplemental oxygen therapy for exercise\n* Age: 18 to 80 years\n* Participation in an inpatient pulmonary rehabilitation program (Schoen Klinik BGL, Germany)\n* Written informed consent\n\nExclusion Criteria:\n\n\\- Acute exacerbation of underlying pulmonary disease requiring cessation of exercise training.","80 Years",{"count":330,"type":21},15,[24],"Long-term oxygen therapy is a fundamental treatment modality for patients with chronic hypoxaemic lung disease. Typically, oxygen is administered at a constant flow rate. However, due to fluctuating activity levels, patients' oxygenation status can vary, potentially leading to oxygen desaturation and increased dyspnoea.\n\nEmerging evidence suggests that automatic oxygen titration - a method of adjusting oxygen flow in response to current oxygen saturation - may have acute advantages over constant oxygen flow.\n\nThe primary objective of this study is to investigate the effect of automatic oxygen titration compared to prescribed constant oxygen flow rates on patients' perceived dyspnoea during exercise endurance training.",[334,32],"Hypoxaemia","2024-08-12",{"date":337,"type":44},"2024-08-13",{"date":339,"type":44},"2023-08-14",{"date":341,"type":21},"2024-11-30",{"name":343,"class":51},"Schön Klinik Berchtesgadener Land",{"id":345,"slug":346,"hasResults":11,"nctId":347,"briefTitle":348,"officialTitle":349,"acronym":95,"eligibilityCriteria":350,"healthyVolunteers":11,"sex":17,"minAge":351,"maxAge":4,"enrollmentInfo":352,"targetDuration":4,"studyType":22,"phases":353,"briefSummary":354,"conditions":355,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":363,"lastUpdatePostDateStruct":364,"startDateStruct":366,"completionDateStruct":368,"leadSponsor":370,"locationsCount":89},"100539466","telehealth-and-onsite-maintenance-exercise-in-chronic-lung-disease-100539466","NCT06304207","Telehealth and Onsite Maintenance Exercise in Chronic Lung Disease","Comparison of Telehealth and Onsite Supervised Maintenance Exercise Program for Adults With Chronic Lung Disease: A Pilot Randomized Controlled Trial","Inclusion Criteria:\n\n* All adult patients 40 years and older with physician diagnosed Chronic Lung Disease within 2 months of discharge following completion of a traditional onsite outpatient rehabilitation or physical therapy or exercise program for their condition\n* Able to walk independently with or without mobility devices\n* Able to complete a six-minute walk test at discharge with or without supplemental oxygen maintaining an oxygen saturation at or above 85%\n* Able to follow commands and instructions in the English language\n* Have ability to connect to the internet\n\nExclusion Criteria:\n\n* • Those with significant mobility limitations such as those with a history of stroke, neurological comorbidities such as Parkinson's disease or relapsing multiple sclerosis, or significant degenerative osteoarthritis, or any other joint impairments that compromise ability to walk independently with or without an assistive device.\n\n  * Patients who primarily rely on a wheelchair for mobility\n  * Patients with or without supplemental oxygen who are unable to complete a walking test without a drop in oxygen saturation to below 85% at discharge from traditional outpatient rehabilitation\n  * Patients with baseline hemodynamic compromise, unstable angina, a recent myocardial infarction within a week, uncontrollable atrial fibrillation not managed with medications, advanced stage heart failure (New York Heart Association class 4), or those with mechanical circulatory assist devices for the heart such a ventricular assist device (VADs)\n  * Inability to communicate in the English language","40 Years",{"count":177,"type":21},[24],"The goal of this pilot clinical trial is to compare telehealth and onsite supervised maintenance exercise program for adults with Chronic Lung Disease.\n\nThe specific aims of the study are:\n\n* To compare 8-week supervised maintenance program delivered onsite and via tele-rehab with no maintenance for patients with Chronic Lung Disease following discharge from traditional exercise or physical therapy or onsite outpatient rehabilitation programs on clinical outcomes (dyspnea, exercise capacity, physical function, physical activity, and quality of life) at 8 weeks and 4-months post-intervention.\n* To compare the differences in dyspnea, exercise capacity, physical function, physical activity, and quality of life between an 8-week maintenance program delivered onsite and via tele-rehab at 8-weeks and 4-months post-intervention in patients with Chronic Lung Disease following discharge from traditional onsite outpatient rehabilitation.\n\nParticipants in both intervention groups (onsite and tele-rehab) will undergo a baseline onsite assessment followed by an 8-week supervised exercise intervention either onsite or in a telehealth setting. Control group will receive biweekly check in calls, but no active intervention.",[356,357,358,359,32,360,257,256,361,362],"Copd","COPD Exacerbation","COPD Bronchitis","Emphysema or COPD","Pulmonary Fibrosis","Chronic Asthma","Chronic Asthmatic Bronchitis","2024-07-30",{"date":365,"type":44},"2024-08-01",{"date":367,"type":44},"2023-09-01",{"date":369,"type":21},"2026-03-01",{"name":371,"class":51},"MGH Institute of Health Professions",{"id":373,"slug":374,"hasResults":11,"nctId":375,"briefTitle":376,"officialTitle":377,"acronym":378,"eligibilityCriteria":379,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":380,"targetDuration":4,"studyType":22,"phases":382,"briefSummary":384,"conditions":385,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":387,"lastUpdatePostDateStruct":388,"startDateStruct":390,"completionDateStruct":392,"leadSponsor":394,"locationsCount":89},"100555614","phase-1-safety-of-endobronchial-mesenchymal-stromal-cells-in-the-treatment-of-chronic-lung-allograft-dysfunction-100555614","NCT06514378","Safety of Endobronchial Mesenchymal Stromal Cells in the Treatment of Chronic Lung Allograft Dysfunction","An Open Label, Randomised, Controlled Clinical Trial to Asses the Safety of Endobronchial Administration of Allogneic Mesenchymal Stromal Cells in Patients With Lung Trasplant Chronic Rejection: Endosclad Study.","ENDOSCLAD","Inclusion Criteria:\n\nPatients should have signed written informed consent. Adult patients ≥18 years of age at the time of enrolment Patients recipients of a uni or bipulmonary transplant An established diagnosis of BOS ≧ 0p (FEV1≤90% and \u002F or FEF 25-75% ≤ of the baseline value with no other justifying cause) in the last 6 months.\n\nExclusion Criteria:\n\n* History of lobar transplantation History of heart-lung transplantation Active infection at the time of inclusion. Active Acute Rejection not treated at the time of inclusion. Oncological history (except cutaneous basal cell or carcinoma in situ) Systemic autoimmune diseases. Active HIV \u002F HBV \u002F HCV infection (confirmed by serology or PCR) Proximal airway stenosis Pregnancy Performance status 3 or 4 (confined to bed or chair for more than 50% of waking hours, able only to perform some self-care activities) Estimated survival less than 3 months. Known hypersensitivity to components used in the production of allogeneic MSCs. Any circumstance that, in the opinion of the investigator, compromises the patient's ability to participate in the clinical trial.",{"count":381,"type":21},12,[383],"PHASE1","Lung transplantation is the only therapeutic alternative for more and more patients with respiratory diseases in their most advanced stages.\n\nThe most limiting factor to achieve long term survival si chronic lung allograft dysfunction, a multifactorial disease without an effective treatment.\n\nThe immunomodulatory capacity of mesenchymal stem cells enables them to be a potential therapeutic agent for this condition.\n\nThe objective of this study is to assess the safety of endobronchial administration of allogeneic MSCs in patients with chroniclung allograft dysfunction.",[32,386],"Lung Transplant Rejection","2024-07-25",{"date":389,"type":44},"2024-07-26",{"date":391,"type":44},"2023-09-19",{"date":393,"type":21},"2026-03-31",{"name":395,"class":51},"Instituto De Investigación Sanitaria Puerta De Hierro-Segovia De Arana",{"id":397,"slug":398,"hasResults":11,"nctId":399,"briefTitle":400,"officialTitle":401,"acronym":402,"eligibilityCriteria":403,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":404,"targetDuration":4,"studyType":22,"phases":406,"briefSummary":407,"conditions":408,"keywords":409,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":413,"lastUpdatePostDateStruct":414,"startDateStruct":416,"completionDateStruct":418,"leadSponsor":420,"locationsCount":89},"100552912","comparing-centre-based-remotely-supervised-and-self-administered-sts-tests-in-individuals-with-crd-100552912","NCT06479252","Comparing Centre-based, Remotely Supervised, and Self-administered STS Tests in Individuals With CRD","Comparing Centre-based, Remotely Supervised, and Self-administered Sit-to-stand Tests in Individuals With Chronic Respiratory Diseases","STS24","Inclusion Criteria:\n\n* Physician diagnosis of chronic respiratory disease (e.g., Chronic Obstructive Pulmonary Disease, Interstitial Lung Disease, Asthma).\n* Male and female patients ≥18 years of age.\n* Able to perform at least 5 repetitions in the 1-min sit-to-stand test without use of upper extremities.\n* Access to a portable pulse oximeter at home to measure heart rate and oxygen saturation.\n* Access to technology for remote supervision (e.g., mobile phone, laptop\u002Fcomputer, iPad)\n\nExclusion Criteria:\n\n* Lower limb surgery in the preceding 3 months.\n* Medically unstable to perform exercise tests (e.g., no exacerbation in the preceding two weeks).\n* Predominant neurological or musculoskeletal limitations to completing sit-to-stand.\n* At risk of falling during sit-to-stand due to impaired balance, as indicated in their clinical record, and\u002For PR assessment.",{"count":405,"type":21},50,[24],"Despite evidence on the psychometric properties of sit-to-stand (STS) tests in chronic respiratory disease (CRD) populations, most studies have been conducted face-to-face. Given the recent emphasis on virtual pulmonary rehabilitation (VPR), there is a need to identify reliable and valid exercise tests that can be delivered in home-based settings, either supervised remotely or self-administered by patients. A repeated-measures crossover design will be used to test the home-based administration of STS tests. The 30-second STS (30-s STS) and 1-minute STS (1-min STS) tests will be randomly administered across three test conditions (centre-based, remotely supervised, and self-administered). Data will summarize the feasibility of remotely supervised and self-administered STS tests and compare the performances of centre-based tests with remotely supervised and self-administered versions of STS tests in patients with CRD.",[32],[410,411,412],"Assessment","Pulmonary Rehabilitation","Remote","2024-07-03",{"date":415,"type":44},"2024-07-08",{"date":417,"type":44},"2024-06-22",{"date":419,"type":21},"2024-12-31",{"name":421,"class":51},"West Park Healthcare Centre",{"id":423,"slug":424,"hasResults":11,"nctId":425,"briefTitle":426,"officialTitle":427,"acronym":4,"eligibilityCriteria":428,"healthyVolunteers":60,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":429,"targetDuration":4,"studyType":65,"phases":4,"briefSummary":431,"conditions":432,"keywords":4,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":434,"lastUpdatePostDateStruct":435,"startDateStruct":437,"completionDateStruct":439,"leadSponsor":441,"locationsCount":4},"100540125","feasibility-of-proteomics-in-chronic-lung-disease-with-sarcopenia-100540125","NCT06312774","Feasibility of Proteomics in Chronic Lung Disease With Sarcopenia","Feasibility Study for Comparative Analysis of Proteome and Single-cell RNA Sequencing in Chronic Lung Disease Patients With and Without Sarcopenia","Inclusion Criteria:\n\n1. Adult patients diagnosed with chronic lung disease (≥ 18years).\n2. Only patients who are willing and able to provide informed consent to participate in the study.\n\nExclusion Criteria:\n\n1. Patients with other major comorbidities that could significantly impact muscle mass and function, such as severe heart failure, advanced liver or kidney disease, uncontrolled diabetes, or malignancies.\n2. Patients with acute exacerbations of their chronic lung disease or any other acute illness at the time of the study. 3. Patients with a history of neuromuscular disorders or disability that could significantly affect muscle mass and function.\n\n4\\. Patients who have undergone recent surgery in the past 6 months or have received specific treatments that could influence muscle mass and function, such as long-term corticosteroid use, chemotherapy, or radiation therapy.\n\n5\\. Patients with life expectancy of less than 6 months 6. Patients who are unable or unwilling to comply with the study protocol or procedures.\n\n7\\. Patients that are unable to give informed consent.",{"count":430,"type":21},49,"Sarcopenia, the loss of muscle mass and strength with ageing, is a prevalent condition in older adults, particularly those with chronic lung diseases like COPD and interstitial lung disease. The condition exacerbates the decline in physical ability, leading to decreased mobility, impaired quality of life, and increased disability. Sarcopenia's prevalence varies across populations, estimated to affect up to 10% of adults over 60 worldwide, with higher rates reported in studies employing consensus definitions of sarcopenia. The prevalence is even higher in patients with chronic lung diseases, reaching up to 26.6%. Sarcopenia's impact on health-related quality of life has been widely investigated. The condition is associated with various comorbidities, including chronic heart failure, obesity, diabetes, and chronic kidney disease, all negatively impacting the quality of life.\n\nThe proposed study's primary aim is to assess the feasibility of the FACS (finding, assessing, confirming, severity) approach in determining sarcopenia's prevalence in the chronic lung disease population. FACS includes screening, strength measurements, and bioelectrical impedance analysis (BIA) to confirm sarcopenia.\n\nThe study will also explore potential mechanisms associated with sarcopenia in this population, using proteome and single-cell transcriptome profiles. These multi-omics approaches provide a comprehensive view of the cellular and molecular changes underlying sarcopenia.In particular, the study will evaluate patient acceptance, time efficiency of each test, and recruitment effectiveness. The outcomes will guide the design and execution of subsequent, larger studies and provide preliminary data for power calculation for the full-scale study.",[433,32],"Sarcopenia","2024-03-14",{"date":436,"type":44},"2024-03-15",{"date":438,"type":21},"2024-04-18",{"date":440,"type":21},"2027-01-04",{"name":442,"class":51},"University College, London"]